Impact of Poly(ADP-Ribose) Polymerase (PARP) and Immune Checkpoint Inhibitor Combinations on the Viability of Triple-Negative Breast Cancer Cells

first_page Download PDF settings Order Article Reprints Font Type: Arial Georgia Verdana Font Size: Aa Aa Aa Line Spacing:    Column Width:    Background: Open AccessAbstract Impact of Poly(ADP-Ribose) Polymerase (PARP) and Immune Checkpoint Inhibitor Combinations on the Viability of Triple-Negative Breast Cancer Cells † by Tusha SharmaTusha Sharma SciProfiles Scilit Preprints.org Google Scholar and Kumaraswamy Naidu ChitralaKumaraswamy Naidu Chitrala SciProfiles Scilit Preprints.org Google Scholar * Department of Engineering Technology, University of Houston, Sugar Land, TX 77479, USA * Author to whom correspondence should be addressed. † Presented at the 3rd International Electronic Conference on Biomolecules, 23–25 April 2024; Available online: https://sciforum.net/event/IECBM2024. Proceedings 2024, 103(1), 37; https://doi.org/10.3390/proceedings2024103037 Published: 12 April 2024 Download keyboard_arrow_down Download PDF Download PDF with Cover Download XML Download Epub Versions Notes Keywords: poly(ADP-ribose) polymerase (PARP); immune checkpoint inhibitor; triple negative breast cancer Background: Breast cancer is one of the most common cancer types and the second most frequent one among women in the United States. Race plays a key role in the prevalence and prognosis of breast cancer, specifically in triple-negative breast cancer, with African American women being highly prevalent compared to white women. Material and Methods: MDA-MB-453 and 231 cell lines were cultured in RPMI-1640 media with 10%FBS. Upon 70–80% confluency, cells were treated with doxorubicin (2 μM for MDA-MB-453 and 1 μM for MDA-MB-231). After 24 h, sensitized cells were treated with inhibitors (Olaparib, O; Niraparib, N; Atezolizumab, A; durvalumab, D; and Pembrolizumab, P) alone as well as with different combinations at a concentration of 100 μM. The drug combinations include: O + N, O + A, O +D, O + P, N + A, N + D, N + P, D + A, A + P, and P + D. Statistical analysis was performed between the treatment groups using the one-way ANOVA. Results: Our results showed that MDA-MB-453 cells treated with the combinations O + N, O + A, O + D, N + A, N + D, N + P, and A + P showed a significant change in viability compared to the doxorubicin-treated group. Results showed that MDA-MB-231 cells, treated with the combinations O + N, O + D, N + A, N + D, N + P, A + P, and D + A, showed a significant change in viability compared to the doxorubicin-treated group. Conclusions: These findings indicate that the inclusion of these inhibitors, along with the chemotherapeutic drug, not only significantly affects the cell viability of breast cancer cells but also may be helpful in the better therapeutic regime and patient prognosis. Author ContributionsConceptualization, K.N.C.; data curation, T.S. and K.N.C.; formal analysis, T.S. and K.N.C.; funding acquisition, K.N.C.; investigation, T.S. and K.N.C.; methodology, T.S. and K.N.C.; project administration, K.N.C.; resources, K.N.C.; software, T.S. and K.N.C.; supervision, K.N.C.; validation, T.S. and K.N.C.; visualization, T.S. and K.N.C.; writing—original draft, T.S. and K.N.C.; writing, review and editing, T.S. and K.N.C. All authors have read and agreed to the published version of the manuscript. FundingWork on the manuscript and its revisions was supported by the National Institute on Minority Health and Health Disparities (NIMHD) of the National Institutes of Health (NIH) to the University of Houston under award number U54MD015946. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Institutional Review Board StatementEthical review and approval were waived for this study due to the usage of cell lines and the study did not involve experiments related to human subjects or animals. Informed Consent StatementPatient consent was waived due to the usage of cell lines and the study did not involve experiments related to human subjects or animals. Data Availability StatementAll the data is provided in the manuscript. Conflicts of InterestThe authors declare no conflicts of interest. Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Share and Cite MDPI and ACS Style Sharma, T.; Chitrala, K.N. Impact of Poly(ADP-Ribose) Polymerase (PARP) and Immune Checkpoint Inhibitor Combinations on the Viability of Triple-Negative Breast Cancer Cells. Proceedings 2024, 103, 37. https://doi.org/10.3390/proceedings2024103037 AMA Style Sharma T, Chitrala KN. Impact of Poly(ADP-Ribose) Polymerase (PARP) and Immune Checkpoint Inhibitor Combinations on the Viability of Triple-Negative Breast Cancer Cells. Proceedings. 2024; 103(1):37. https://doi.org/10.3390/proceedings2024103037 Chicago/Turabian Style Sharma, Tusha, and Kumaraswamy Naidu Chitrala. 2024. "Impact of Poly(ADP-Ribose) Polymerase (PARP) and Immune Checkpoint Inhibitor Combinations on the Viability of Triple-Negative Breast Cancer Cells" Proceedings 103, no. 1: 37. https://doi.org/10.3390/proceedings2024103037 Article Metrics No No Article Access Statistics Multiple requests from the same IP address are counted as one view.